SCHEMBL5582767

SCHEMBL5582767

O=C(O)c1ccc(OCc2ccc(-c3ccccc3)cc2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 4/20 0.81
NR4A1 P22736 1/20 0.81
NR4A3 Q92570 1/20 0.81
SRD5A2 P31213 1/20 0.73
PTGES O14684 1/20 0.70
ALOX5 P09917 1/20 0.70
PLA2G4B P0C869 1/20 0.69
RXRA P19793 6/20 0.69
RXRB P28702 6/20 0.69
NPC1 O15118 1/20 0.69
POLB P06746 1/20 0.69
RAB9A P51151 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
FFAR1 O14842 1/20 0.68
RXRG P48443 1/20 0.63
GSTP1 P09211 1/20 0.62
MAOB P27338 1/20 0.61
PARP10 Q53GL7 1/20 0.61
PTPN1 P18031 2/20 0.60
PTPRC P08575 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1756343 1.00 NR4A2 (0.81) NR4A2NR4A1NR4A3SRD5A2PTGES
SCHEMBL4949143 0.95 NR4A2 (0.90) NR4A2NR4A1NR4A3SRD5A2PTGES
Hydrochloric Acid SCHEMBL8378883 0.93 NR4A2 (0.87) NR4A2NR4A1NR4A3SRD5A2PTGES
SCHEMBL18625354 0.91 NR4A2 (0.77) NR4A2NR4A1NR4A3SRD5A2PTGES
SCHEMBL7539817 0.90 SRD5A2 (0.73) NR4A2NR4A1NR4A3SRD5A2PTGES
SCHEMBL6830467 0.90 NR4A2 (1.00) NR4A2NR4A1NR4A3SRD5A2PLA2G4B
SCHEMBL228477 0.90 NR4A2 (1.00) NR4A2NR4A1NR4A3SRD5A2PLA2G4B
SCHEMBL4059143 0.90 NR4A2 (1.00) NR4A2NR4A1NR4A3SRD5A2PLA2G4B
SCHEMBL1750167 0.90 NR4A2 (0.86) NR4A2NR4A1NR4A3SRD5A2PLA2G4B
SCHEMBL8134318 0.89 NR4A2 (0.85) NR4A2NR4A1NR4A3SRD5A2PLA2G4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-7115750-B1 Melanin concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-10-03 US disclosed
US-6586475-B1 5-chloro-N-(2-N,N-diethylamino)ethyl)-2- methoxy-4-(1-naphthoylamino)benzamide and prodrugs, used for prevention of neurodegenarative diseases such as Alzheimer's disease TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-07-01 US disclosed
EP-1218336-A2 MELANIN CONCENTRATING HORMONE ANTAGONIST Takeda Chemical Industries, Ltd. (JP) 2002-07-03 EP disclosed
EP-1132376-A1 BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS Takeda Chemical Industries, Ltd. (JP) 2001-09-12 EP disclosed
WO-2001021577-A2 MELANIN CONCENTRATING HORMONE ANTAGONIST TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-03-29 WO disclosed
CN-1082023-A The medicine and the novel benzoic acid derivative that contain benzoic acid derivative YAMANOUCHI PHARMA CO LTD (JP) 1994-02-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173498-A1 Melanin concentrating hormone antagonist MC1R, MCHR1, MCHR2 NR4A2 214/4885NR4A1 153/4885NR4A3 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.